Tango Therapeutics enhances board of directors adding Oncology Experts
Tango Therapeutics which is a biotechnology company creating novel, targeted medicines for specific cancer subtypes claimed the addition of three experienced leaders with deep backgrounds in personalized cancer research, drug discovery and development to the board of directors.
Michael Pellini, M.D., MBA, chairman of Foundation Medicine and managing partner at Section 32; Allen Oliff, M.D., an oncologist and senior vice president in research and development at GlaxoSmithKline; and Pablo Cagnoni, M.D., the president and chief executive officer of Tizona Therapeutics. All are leading experts in oncology R&D.
Barbara Weber, M.D., Tango’s chief executive officer said “Their expertise, insights and commitment to this field will help Tango immensely as we create a new generation of breakthrough cancer therapies.”